Evidence map›Paper›PMID 36624530›Full record

ArticleMicrobiome2023

Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes.

Jonathan P Jacobs, Venu Lagishetty, Megan C Hauer, Jennifer S Labus, Tien S Dong, Ryan Toma, Momchilo Vuyisich, Bruce D Naliboff, Jeffrey M Lackner, Arpana Gupta and 2 more

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Microbiome, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 5 pooled it
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 5 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Irritable bowel syndrome.Nature reviews. Disease primers · 2026
    Review
  8. Review
  9. Low-Molecular-Weight Peptides fromInternational journal of molecular sciences · 2026
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jonathan P JacobsVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. JJacobs@mednet.ucla.edu.
Venu LagishettyVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Megan C HauerVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Jennifer S LabusVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Tien S DongVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Ryan TomaViome Life Sciences, Bellevue, WA, USA.
Momchilo VuyisichViome Life Sciences, Bellevue, WA, USA.
Bruce D NaliboffVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Jeffrey M LacknerDivision of Behavioral Medicine, Department of Medicine, Jacobs School of Medicine, University at Buffalo, SUNY, Buffalo, NY, USA.
Arpana GuptaVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Kirsten TillischVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Emeran A MayerVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. emayer@ucla.edu.
University of California, Los Angeles · USBellevue Hospital Center · USUniversity at Buffalo, State University of New York · US

Funding

Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
The role of brain-gut microbiome interactions in mediating IBS and constipation symptoms during menses and menopauseU54DK123755 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Lin Chang, Elaine Hsiao · 2020 to 2026
$10.5M
PERCEPTION AND MODULATION OF VISCERAL SENSATIONSR01DK048351 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MAYER, EMERAN A · 1996 to 2019
$8.2M
Self-Administered CBT for IBS: A Multicenter TrialU01DK077738 · NIDDK · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LACKNER, JEFFREY M · 2008 to 2014
$8.1M
Neurobiological mechanisms underlying effectiveness of CBT in IBS patientsR01DK096606 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LACKNER, JEFFREY M, MAYER, EMERAN A · 2012 to 2015
$1.9M
Role of Inflammatory Processes in Reward Network Alterations in ObesityK23DK106528 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHURCH, ARPANA · 2016 to 2020
$1.0M
Role of the Gut Microbiome in Reward Network Alterations in ObesityR03DK121025 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHURCH, ARPANA · 2020 to 2021
$234k
Modulation of the Intestinal Microbiome in Obesity by a High Protein DietIK2CX001717 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI JACOBS, JONATHAN PATRICK · 2018 to 2023
–
CSRD VA IK2 CX001717NIDDK NIH HHS K23 DK106528NIDDK NIH HHS P30 DK041301NIDDK NIH HHS R01 DK048351NIDDK NIH HHS R01 DK096606NIDDK NIH HHS R03 DK121025NIDDK NIH HHS U01 DK077738NIDDK NIH HHS U54 DK123755
6 · The paper itself

Abstract

backgroundIrritable bowel syndrome (IBS) is a common gastrointestinal disorder that is thought to involve alterations in the gut microbiome, but robust microbial signatures have been challenging to identify. As prior studies have primarily focused on composition, we hypothesized that multi-omics assessment of microbial function incorporating both metatranscriptomics and metabolomics would further delineate microbial profiles of IBS and its subtypes.

methodsFecal samples were collected from a racially/ethnically diverse cohort of 495 subjects, including 318 IBS patients and 177 healthy controls, for analysis by 16S rRNA gene sequencing (n = 486), metatranscriptomics (n = 327), and untargeted metabolomics (n = 368). Differentially abundant microbes, predicted genes, transcripts, and metabolites in IBS were identified by multivariate models incorporating age, sex, race/ethnicity, BMI, diet, and HAD-Anxiety. Inter-omic functional relationships were assessed by transcript/gene ratios and microbial metabolic modeling. Differential features were used to construct random forests classifiers.

resultsIBS was associated with global alterations in microbiome composition by 16S rRNA sequencing and metatranscriptomics, and in microbiome function by predicted metagenomics, metatranscriptomics, and metabolomics. After adjusting for age, sex, race/ethnicity, BMI, diet, and anxiety, IBS was associated with differential abundance of bacterial taxa such as Bacteroides dorei; metabolites including increased tyramine and decreased gentisate and hydrocinnamate; and transcripts related to fructooligosaccharide and polyol utilization. IBS further showed transcriptional upregulation of enzymes involved in fructose and glucan metabolism as well as the succinate pathway of carbohydrate fermentation. A multi-omics classifier for IBS had significantly higher accuracy (AUC 0.82) than classifiers using individual datasets. Diarrhea-predominant IBS (IBS-D) demonstrated shifts in the metatranscriptome and metabolome including increased bile acids, polyamines, succinate pathway intermediates (malate, fumarate), and transcripts involved in fructose, mannose, and polyol metabolism compared to constipation-predominant IBS (IBS-C). A classifier incorporating metabolites and gene-normalized transcripts differentiated IBS-D from IBS-C with high accuracy (AUC 0.86).

conclusionsIBS is characterized by a multi-omics microbial signature indicating increased capacity to utilize fermentable carbohydrates-consistent with the clinical benefit of diets restricting this energy source-that also includes multiple previously unrecognized metabolites and metabolic pathways. These findings support the need for integrative assessment of microbial function to investigate the microbiome in IBS and identify novel microbiome-related therapeutic targets. Video Abstract.

Indexed as

Gastrointestinal MicrobiomeIrritable Bowel SyndromeCraniosynostosesFecesHabitsHumansIntellectual DisabilityMultiomicsRNA, Ribosomal, 16SRNA, Ribosomal, 16SBiomarkersBowel habit subtypesIrritable bowel syndromeMetabolomicsMetatranscriptomicsMicrobiomeMulti-omics

Identifiers

PMID36624530
PMCPMC9830758
OpenAlexW4313880505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.